[Support Us]
CMIR has received financial support from the National Institutes of Health (NCI, NIBIB, NHLBI, NIDDK, NIAID), NSF, NASA, DOD, DOE, Dana Farber/Harvard Cancer Center (DFHCC), Reynolds Foundation, National Foundation for Cancer Research (NFCR), Breast Cancer Research Foundation (BCRF), Broad Foundation, Susan B. Komen Foundation, American Brain Tumor Association, American Heart Association (AHA), Charles Dana Foundation, Avon Breast Cancer Foundation, CapCure Foundation, Siemens Medical Systems, Schering AG, General Electric (GE), Advanced Magnetics Inc., and Millenium Pharmaceuticals among others.

The above sources of the funding are all ear-marked for specific projects and protocols, allowing little flexibility or opportunity to fund the type of innovative clinical research that CMIR aims to conduct. Flexible funds to conduct clinical trials, foster new initiatives, support researchers who need the funds to pursue innovative approaches and research are thus critically needed. Many of the exciting breakthroughs that occur in clinical research and lead to the development of new diagnostic tools require this type of initial backing.

Your support can make the difference!

For more information on how you can support CMIR, please contact Dr. Ralph Weissleder at 617-726-8226 or weissleder@helix.mgh.harvard.edu .

Click here to make a contribution
[Organization Status]
CMIR is part of Massachusetts General Hospital, a tax-exempt, 501(c)3, nonprofit organization headquartered in Boston, Ma (Federal Tax ID 04-269-7983).